BioMarin, MSD sue Aurobindo over rare disease drug

BioMarin Pharmaceutical and MSD (known as 'Merck & Co' in the US), have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan (Sapropterin hydrochloride), used to treat a rare genetic disorder.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BioMarin accuses engineer of stealing 1,800 files

23 November 2021 BioMarin Pharmaceuticals has accused a former engineer who went to work for competitor Sangamo Therapeutics of stealing more than 1,800 files containing confidential information and trade secrets.

Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

20 July 2017 Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

Generics

MSD hit with €39m fine over contraceptive generic delay

26 October 2022 The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

More on this story

Americas

BioMarin accuses engineer of stealing 1,800 files

Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

20 July 2017 Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

Generics

MSD hit with €39m fine over contraceptive generic delay

26 October 2022 The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

More on this story

Americas

BioMarin accuses engineer of stealing 1,800 files

Americas

Sarepta and Biomarin resolve patent dispute with $35m licence

20 July 2017 Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.

Generics

MSD hit with €39m fine over contraceptive generic delay

26 October 2022 The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

BioMarin, MSD sue Aurobindo over rare disease drug

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features